Rifabutin for experimental pneumococcal meningitis

Chemotherapy

Volumn 43, Issue 4, 1997, Pages 264-271

  Schmidt, H ^a   Zysk, G ^a   Reinert, R R ^b   Bruck W ^a   Stringaris, A ^a   Chen, V ^a   Stuertz, K ^a   Fischer, F ^a   Bartels, R ^c   Schaper, K J ^c   Weinig, S ^d   Nau, R ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^c RESEARCH CENTER BORSTEL   (Germany)

^d harmacia GmbH   (Germany)

Author keywords

Bactericidal effect; Immunomodulation; Meningitis; Rifabutin; Streptococcus pneumoniae

Indexed keywords

CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; RIFABUTIN; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL MENINGITIS; BACTERICIDAL ACTIVITY; CEREBROSPINAL FLUID; EXPERIMENTAL INFECTION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RABBIT; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE;

EID: 0030976139     PISSN: 00093157     EISSN: 14219794     Source Type: Journal    
DOI: 10.1159/000239577     Document Type: Article

References (22)

1. Wenger JD, Hightower AW, Fack-lam RR. Gaventa S, Broome CV: Bacterial Meningitis Study Group. Bacterial meningitis in the United States, 1986: Report of multistate surveillance study. J Infect Dis 1990:162:1316-1323.
2. Durand ML, Caldcrwood SB, Weber DJ, Miller SI, Southwick FS, Caviness VS, Swartz MN: Acute bacterial meningitis in adults: A review of 493 episodes. N Engl J Med 1993;328:21-28.
3. Mustafa MM, Ramilo O, Mertsola J. Risscr RC, Beutler B, Hansen EJ, McCracken GH: Modulation of inflammation and cachcctin activity in relation to treatment of experimental Haemophilus influenzae type b meningitis. J Infect Dis 1989; 160:818-825.
4. Tuomanen E, Hengstier B, Rich R, Bray MA, Zak O, Tomasz A: Nonsteroidal anti-inflammatory agents in the therapy for experimental pneumococcal meningitis. J Infect Dis 1987;155:985-990.
5. Burroughs M, Rozdzinski E, Geelen S, Tuomanen E: A structurc-activity relationship for induction of meningeal inflammation by muramyl peptides. J Clin Invest 1993;92:297-302.
6. Riesenfeld-Orn I, Wolpe S, Garcia-Bustos JF, Hoffman MK, Tuomanen EI: Production of interleukin-1 but not tumor necrosis factor by human monocytes stimulated with pneumococcal cell surface components. Infect Immun 1989,57:1890-1893.
7. Kim YS, Kennedy S, Täuber MG: Toxicity of Streptococcus pneumoniae in neurons, astrocytes, and microglia in vitro. J Infect Dis 1995: 171:1363-1368.
8. Kim YS, Tauber MG: Neurotoxicity of glia activated by gram-positive bacterial products depends on nitric oxide production. Infect Immun 1996;64:3148-3153.
9. Brogden RN, Fitton A: Rifabutin: A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1994;47:983-1009.
10. Täuber MG, Burroughs M, Niemöller NM, Küster H, Borschberg U, Tuomanen E: Differences of pathophysiology in experimental meningitis caused by three strains of Streptococcus pneumoniae. J Infect Dis 1991;163:806-811.
11. Bartels H, Bartels R: Determination of rifabutin by high-performance liquid chromatography using on-line concentration and column switching. J Chromatogr 1996:686:235-240.
12. Flick DA, Gifford GE: Comparison of in vitro cell cytotoxic assays for tumor necrosis factor. J Immunol Meth 1984;68:167-175.
13. Zysk G, Brück W, Gerber J, Brück Y, Prange HW, Nau R: Anti-inflammatory treatment influences neuronal apoptotic cell death in the dentate gyrus in experimental pneumococcal meningitis. J Neuropath Exp Neurol 1996;55:722-728.
14. Gold R, Schmied M, Rothe G: Detection of DNA fragmentation in apoptosis: Application of in situ nick translation to cell culture systems and tissue sections. J His-tochem Cytochem 1993:41:1023-1030.
15. Nau R, Kaye K, Sachdeva M, Sande ER, Täuber MG: Rifampicin for therapy of experimental pneumococcal meningitis in rabbits. Antimi-crob Agents Chemother 1994,38: 1186-1189.
16. Nau R, Schmidt T, Kaye K, Froula JL, Täuber MG: Quinolone antibiotics in therapy of experimental pneumococcal meningitis in rabbits. Antimicrob Agents Chemother 1995;39:593-597.
17. Dofferhoff ASM, Nijland JH, de Vries-Hospcrs HG, Mulder PO, Weits J, Bom VJ: Effects of different types and combinations of antimicrobial agents on endotoxin release from gram-negative bacteria: An in-vitro and in-vivo study. Scand J Infect Dis 1991;23:745-754.
18. Jackson JJ, Kropp H: G-Lactam antibiotic-induced release of free endotoxin: In vitro comparison of penicillin-binding protein (PBP) 2-specific imipenem and PBP 3-spccific ceftazidime. J Infect Dis 1992; 165: 1033-1041.
19. Prins JM, Kuijper EJ, Mevissen ML, Speelman P, van Deventer SJ: Release of tumor necrosis factor alpha and interleukin 6 during antibiotic killing of Escherichia coli in whole blood: influence of antibiotic class, antibiotic concentration, and presence of septic serum. Infect Immun 1995;63:2236-2242.
20. Evans ME, Pollack M: Effect of antibiotic class and concentration on the release of lipopolysaccharide from Escherichia coli. J Infect Dis 1993; 167:1336-1343.
21. Buss WC, Morgan R, Guttman J, Barela T, Staltcr K: Rifampicin inhibition of protein synthesis in mammalian cells. Science 1978:200: 232-234.
22. Guerra-Romero L, Täuber MG, Fournier MA, Tureen JH: Lactate and glucose concentrations in brain interstitial fluid, cerebrospinal fluid, and serum during experimental pneumococcal meningitis. J Infect Dis 1992;166:546-550.